EN | UA
EN | UA

Help Support

Back

Serum calprotectin proves to be a potential biomarker for assessing disease activity in rheumatic diseases

Serum calprotectin proves to be a potential biomarker for assessing disease activity in rheumatic diseases Serum calprotectin proves to be a potential biomarker for assessing disease activity in rheumatic diseases
Serum calprotectin proves to be a potential biomarker for assessing disease activity in rheumatic diseases Serum calprotectin proves to be a potential biomarker for assessing disease activity in rheumatic diseases

What's new?

Serum calprotectin is a useful biomarker for tracking disease activity; detect inflammatory disease in patients complaining of arthralgia, neutrophil initiation (more effective as compared to CRP) and, severity of disease and prognosis in RA and axSpA.

A recent study published in May of ‘Arthritis Research & Therapy’ confirmed about the relationship of serum calprotectin levels with disease activity in both rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA), except in psoriatic arthritis (PsA).

Calprotectin or S100A8/S100A9 protein is recognized as a damage-associated molecular pattern protein and indicates primarily neutrophil activation. Matthias Jarlborg et al. examined whether the serum calprotectin is associated with disease activity and severity in RA, axSpA, and PsA.

On the whole, 1729 patients were included from the Swiss Clinical Quality Management (SCQM) registry. Out of these, 969 were RA patients, 451 were axSpA patients and 237 were PsA patients. And, 72 asymptomatic first-degree relatives of patients with RA were regarded as healthy controls (HC). Their serum calprotectin was calculated. Different outcomes were used for the 3 rheumatic diseases as:

  • RA patients: Swollen joint count (SJC), Disease Activity Score (DAS), Health Assessment questionnaire (HAQ), joint radiographs, and ultrasound power Doppler (USPD) was used;
  • AxSpA patients: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS) and coxitis; and
  • PsA patients: SJC and Disease Activity Index for PSoriatic Arthritis (DAPSA)

The Kruskal-Wallis tests were used to compare the outcomes by calprotectin quartile levels for continuous outcomes or trend tests for categorical outcomes.

As found, in every disease group, the median levels of serum calprotectin were higher than HC. All the clinical outcomes were found to be statistically different amongst quartiles of serum calprotectin, demonstrating a possible link between calprotectin levels and higher disease activity (SJC, DAS, and USPD scores) and severity (joint radiographs and HAQ). An association between the levels of calprotectin and ASDAS score and occurrence of coxitis was revealed in axSpA. The SJC and DAPSA did not vary across calprotectin quartiles for PsA patients.

Source:

Arthritis Research & Therapy

Article:

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis

Authors:

Matthias Jarlborg et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: